Clinical Trials
564 trialsSTELLAR-002
Exelixis
ATHENA
AstraZeneca
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
INDIGO
Boston Scientific Corporation
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
SillaJen, Inc.
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
IMFINZI-subQ
AstraZeneca
LEAP-012
Merck Sharp & Dohme LLC
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
Guangzhou FineImmune Biotechnology Co., LTD.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
TREMENDOUS-2
AstraZeneca
ARTEMIDE-HCC01
AstraZeneca
MWA Sim
NE Scientific INC
Wondercel-UWD3
Wondercel Biotech (ShenZhen)
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Kirros
Genentech, Inc.
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
ROWAN
Boston Scientific Corporation
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
GDFATHERHCC01
CatalYm GmbH
KEYNOTE-937
Merck Sharp & Dohme LLC
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Huahui Health
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Teclison Ltd.
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
TATE-PD1
Teclison Ltd.
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
EMERALD-1
AstraZeneca
BANTAM-01
Bayer
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
T-ACE Medical Co., Ltd
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
GPC3
RayzeBio, Inc.
SELECT-2CAR
Beijing Biotech
PRESERVE-009
OncoC4, Inc.
EMERALD-3
AstraZeneca
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
CheckMate 9DW
Bristol-Myers Squibb
RHEA-1
AstraZeneca